In this July 27, 2020, file photo, nurse Kathe Olmstead prepares a shot that is part of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, N.Y. Moderna said Monday, Nov. 16, 2020, its COVID-19 shot provides strong protection against the coronavirus that's surging in the U.S. and around the world. (AP Photo/Hans Pennink, File)
For the second time this month, there's promising news from a COVID-19 vaccine candidate: Moderna said Monday its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the U.S. and around the world.
Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from the company’s still ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the U.S.
Dr. Stephen Hoge, Moderna’s president, welcomed the “really important milestone” but said having similar results from two different companies is what’s most reassuring.
“That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” Hoge told The Associated Press.
“It won’t be Moderna alone that solves this problem. It’s going to require many vaccines” to meet the global demand, he added.
A vaccine can’t come fast enough, as virus cases topped 11 million in the U.S. over the weekend — 1 million of them recorded in just the past week. The pandemic has killed more than 1.3 million people worldwide, more than 245,000 of them in the U.S.
Still, if the Food and Drug Administration allows emergency use of Moderna’s or Pfizer’s candidates, there will be limited, rationed supplies before the end of the year. Both require people to get two shots, several weeks apart. Moderna expects to have about 20 million doses, earmarked for the U.S., by the end of 2020. Pfizer and its German partner BioNTech expect to have about 50 million doses globally by year’s end.
Moderna’s vaccine, created with the National Institutes of Health, is being studied in 30,000 volunteers who received either the real vaccination or a dummy shot. On Sunday, an independent monitoring board broke the code to examine 95 infections that were recorded starting two weeks after volunteers' second dose — and discovered all but five illnesses occurred in participants who got the placebo.
The study is continuing, and Moderna acknowledged the protection rate might change as more COVID-19 infections are detected and added to the calculations. Also, it’s too soon to know how long protection lasts. Both cautions apply to Pfizer’s vaccine as well.
But Moderna’s independent monitors reported some additional, promising tidbits: All 11 severe COVID-19 cases were among placebo recipients, and there were no significant safety concerns.
The main side effects were fatigue, muscle aches and injection-site pain after the vaccine’s second dose, at rates that Hoge characterized as more common than with flu shots but on par with others such as shingles vaccine.
Moderna shares rocketed higher on the announcement and appeared to be headed for an all-time high Monday. The Cambridge, Massachusetts, company's vaccine is among 11 candidates in late-stage testing around the world, four of them in huge studies in the U.S.
Both Moderna's shots and the Pfizer-BioNTech candidate are so-called mRNA vaccines, a brand-new technology. They aren’t made with the coronavirus itself, meaning there’s no chance anyone could catch it from the shots. Instead, the vaccine contains a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus.
The strong results were a surprise. Scientists have warned for months that any COVID-19 shot may be only as good as flu vaccines, which are about 50% effective.
Another steep challenge: distributing doses that must be kept very cold. Both the Moderna and Pfizer shots are frozen but at different temperatures. Moderna announced Monday that once thawed, its doses can last longer in a refrigerator than initially thought, up to 30 days. Pfizer's shots require long-term storage at ultra-cold temperatures.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Catching you up on what you need to know on April 26, 2022, with Elon Musk’s purchase of Twitter for $44 billion, Russia warning of a possible threat of World War III, the FDA approving a COVID treatment for children under 12, and more.
Plastic pollution is a problem that experts say is only getting worse. One organization is looking to change that. Activists want to save the beauty of our oceans, with the beauty of art. Brad Parks, conservation education director of the Washed Ashore project, joins Cheddar News to discuss.
The federal mask mandate for planes and other public transportation has been grounded. A federal judge in Florida struck down the nationwide requirement saying it exceeds health officials' authority. Dr. Sampson Davis, emergency medicine physician, joins Cheddar News to discuss.
UPSIDE foods, a company that makes cultivated meat products, recently raised $400 million in a Series C round.
UPSIDE says it's developing a way to grow real meat, poultry, and seafood, without the need to raise animals for human consumption. It's a process that gets the attention of some big-name backers, including Bill Gates and Richard Branson. Dr. Uma Valeti, Founder and CEO of UPSIDE Foods, joins Cheddar News' Closing Bell to discuss.
Catching you up on what you need to know on April 25, 2022, with Secretary of State Blinken and Defense Secretary Austin visiting Ukraine, Emmanuel Macron is reelected as president of France, Twitter is talking to Elon Musk about his purchase bid, and more.
An increasing number of countries are recognizing "Rights of Nature", a legal movement that says ecosystems and species have basic rights to exist and flourish. Grant Wilson, executive director at Earth Law Center joins Cheddar News to explain what the movement is aiming to achieve.
Removing carbon from our atmosphere has become a goal for scientists and entrepreneurs around the world, and while many have begun to develop promising technology solutions, a few big names in tech, including Stripe, Alphabet, Shopify, Meta and McKinsey, are committing nearly $1 billion dollars to fund carbon removal technology through 2030 through a new initiative called Frontier, an advanced market commitment to incentive following through on development. Hannah Bebbington, the head of strategy for Frontier, joined Cheddar News to discuss. "What Frontier aims to do is help get this market on track by sending that strong demand signal such that we can scale up capacity really significantly in the next couple of years," she said.
Autumn Peltier, an indigenous water activist, joined Cheddar News to talk about the lack of access to clean water among indigenous communities in Canada. “I say the government to hold themselves accountable for the promises that they make because Canada and indigenous people have a long history of broken promises and they still continue to this day to keep breaking promises with the nation's people," she said. "Less talk and more action is very much expected from me."
Jonah Goldman, the managing director at Bill Gates-founded Breakthrough Energy, joined Cheddar News to talk about the promising growth in the climate change-conscious investments the organization has made over the years. ”I mean when we're looking at some of the hard to abate technologies and cement and steel and aviation fuel, all of those have promising pathways that weren't there again just a few years ago," he said. "We invest across all of the technology areas that are driving emissions, greenhouse gas emissions and there really are exciting products and technologies coming out in almost every one of those sectors.”
Robert Bonnie, farm production and conservation undersecretary for the USDA, spoke to Cheddar about climate-smart strategies to help farmers reduce carbon emissions from agriculture. "We share the costs of installing those practices on their lands in ways that will protect the climate and maintain agricultural productivity, and we're also partnering with farmers to draw in private investment in greenhouse gas emissions reductions provided by agriculture and forestry," he said. The hope is to get farmers and ranchers to produce climate-smart commodities to lessen the impact of climate change.
